No - this analysis would explain why they may be shorting Neuren if what Little T had heard is correct. My point is that they clearly value Daybue poorly (incorrectly in my opinion) and IF they have a limited understanding of 2591s potential or just rarely put much weight on phase 2 assets then they would look at Neuren as overvalued and a short target. Unlike myself and others, no doubt, who think Neuren is undervalued
No - this analysis would explain why they may be shorting Neuren...
-
- There are more pages in this discussion • 788 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
-0.040(0.26%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $8.124M | 524.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | $15.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.58 | 597 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |